"10.1371_journal.pone.0107213","plos one","2014-09-26T00:00:00Z","Lilia Maneva-Radicheva; Christina Amatya; Camille Parker; Jacob Ellefson; Ilian Radichev; Arvind Raghavan; Matthew L Charles; Mark S Williams; Mark S Robbins; Alexei Y Savinov","Sanford Project/Children’s Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America; DiaMedica USA, Inc., Minneapolis, Minnesota, United States of America","Conceived and designed the experiments: LM-R MSW MLC AYS. Performed the experiments: LM-R CA CP JE IR. Analyzed the data: LM-R CA IR AR MLC MSW MSR AYS. Contributed reagents/materials/analysis tools: MSW MLC AYS. Wrote the paper: LM-R AR MSW MSR AYS.","MLC, MSW and MSR are employees and shareholders of Diamedica USA, Inc. AR is a consultant for Diamedica USA, Inc. The authors (indicated in parentheses) are inventors on the following patents covering compositions and/or the use of human tissue kallikrein for treating diabetes: PCT/ CA2010/000413, ‘Tissue kallikrein for the treatment of pancreatic beta cell dysfunction’ (MSW); PCT/US2012/036556, ‘Compositions and methods for treating diabetes (MLC and MSW); PCT/CA2013/050395, ‘Formulations of human tissue kallikrein-1 for parenteral delivery and related methods’ (MLC). DM199 is currently in clinical trials for the treatment of type 2 diabetes. There are no further relevant patents, products in development or marketed products to declare. These competing interests do not alter the authors adherence to all the PLOS ONE policies on sharing data and/or materials.","2014","09","Lilia Maneva-Radicheva","LMR",10,TRUE,4,5,8,5,TRUE,TRUE,FALSE,0,NA,FALSE
